Literature DB >> 9361090

Altered expression of insulin-like growth factor II receptor in human pancreatic cancer.

T Ishiwata1, U Bergmann, M Kornmann, M Lopez, H G Beger, M Korc.   

Abstract

The insulin-like growth factor-II (IGF-II) receptor (IGF-IIR) is a single-chain transmembrane protein identical to the mannose-6-phosphate receptor. In the present study we examined IGF-IIR expression in normal and cancerous human pancreatic tissues. In the normal pancreas, moderately strong IGF-IIR immunoreactivity was present in the cytoplasm of islet cells, and mild cytoplasmic immunoreactivity was evident occasionally in ductal and acinar cells. Some ductal cells also exhibited nuclear IGF-IIR immunoreactivity. In the pancreatic cancers, regions of strong IGF-IIR immunoreactivity were present in the duct-like cancer cells within the tumor mass, often exhibiting nuclear localization. Expression of IGF-IIR mRNA in the cancer cells was confirmed by in situ hybridization. By comparison with normal pancreatic tissues, 7 of 12 pancreatic cancers exhibited a 5.6-fold increase in IGF-IIR mRNA levels, whereas in 3 cancers the IGF-IIR transcript was below the level of detection. Furthermore, all six tested cultured human pancreatic cancer cell lines expressed the IGF-IIR mRNA transcript. Our data indicate that IGF-IIR is overexpressed in a significant number of human pancreatic cancers, where it has a tendency to localize in the nucleus, and raise the possibility that IGF-IIR may contribute to the pathobiology of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361090     DOI: 10.1097/00006676-199711000-00006

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Soft drink and juice consumption and risk of pancreatic cancer: the Singapore Chinese Health Study.

Authors:  Noel T Mueller; Andrew Odegaard; Kristin Anderson; Jian-Min Yuan; Myron Gross; Woon-Puay Koh; Mark A Pereira
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

3.  IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Authors:  Kevin Chu Foy; Megan J Miller; Jay Overholser; Siobhan M Donnelly; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

4.  Insulin-like growth factor 2 enhances insulinogenic differentiation of human eyelid adipose stem cells via the insulin receptor.

Authors:  H M Kang; S Park; H Kim
Journal:  Cell Prolif       Date:  2011-06       Impact factor: 6.831

5.  A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.

Authors:  Donghang Zheng; Vita Golubovskaya; Elena Kurenova; Cheng Wood; Nicole A Massoll; David Ostrov; William G Cance; Steven N Hochwald
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

6.  FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.

Authors:  Weiguo Liu; David A Bloom; William G Cance; Elena V Kurenova; Vita M Golubovskaya; Steven N Hochwald
Journal:  Carcinogenesis       Date:  2008-02-07       Impact factor: 4.944

7.  Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer.

Authors:  T Ishiwata; H Friess; M W Büchler; M E Lopez; M Korc
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 8.  Apoptosis: targets in pancreatic cancer.

Authors:  Sabine Westphal; Holger Kalthoff
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

Review 9.  Pathways for aberrant angiogenesis in pancreatic cancer.

Authors:  M Korc
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

Review 10.  Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.

Authors:  Ayse Ceren Mutgan; H Erdinc Besikcioglu; Shenghan Wang; Helmut Friess; Güralp O Ceyhan; Ihsan Ekin Demir
Journal:  Mol Cancer       Date:  2018-02-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.